GlaxoSmithKline's hope to rejoin the race to vaccinate the world against COVID-19 received a boost after the vaccine candidate the company has jointly developed with French pharmaceutical major Sanofi demonstrated strong immune responses in all adult age groups in preliminary trials, AP reported
After two doses of the vaccine candidate, participants showed neutralising antibodies in line with those found in people who had recovered from the disease, according to results of the Phase 2 trial released on Monday.
The results were from a Phase 2 trial involving 722 volunteers aged 18 to 95 who were recruited in the US and Honduras.
The companies said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vaccine before the end of 2021. The late-stage trial will involve about 37,000 participants from countries around the world, the companies said.
The vaccine suffered a major setback last December, when the companies announced that their joint vaccine candidate did not appear to work well in older adults and that they would have to delay plans to test it in a Phase 3 trial, the crucial test that will assess the vaccine’s effectiveness.
The Sanofi-GSK vaccine was an important part of the European Union's vaccination strategy, and had notably been championed by French President Emmanuel Macron's government. Sanofi’s failure was viewed in France as the decline of country’s scientific prowess.
Sanofi and GSK’s vaccine was one of six selected for funding from Operation Warp Speed, the Trump administration’s effort to accelerate vaccine development
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.